How would you approach the decision to escalate DMT in a patient with relapsing multiple sclerosis who has two to three new T2 lesion but no clinical symptoms?

I would escalate to higher-efficacy DMT in this scenario. As highlighted in the linked article, new T2 lesions show that the patient is at heightened risk for clinical relapses and their disease activity is not well controlled. In the linked study, included patients were on low efficacy DMT (interfe...